Rituximab

(Rituxan®)

Rituxan®

Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 100 mg/10 mL [10 mg/mL] and 500 mg/50 mL [10 mg/mL])
Drug ClassCD20-directed cytolytic antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B cell Non-Hodgkin’s Lymphoma (NHL) as a single agent.
  • Indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin’s Lymphoma (NHL) in combination with first line chemotherapy and, in adult patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single-agent maintenance therapy.
  • Indicated for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20- positive, B-cell Non-Hodgkin’s Lymphoma (NHL) as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
  • Indicated for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin’s Lymphoma (NHL) in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
  • Indicated for the treatment of pediatric patients aged 6 months and older with mature B-cell Non-Hodgkin’s Lymphoma (NHL) and mature B-cell acute leukemia (B-AL) - previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
  • Indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL) in combination with fludarabine and cyclophosphamide (FC).
  • Indicated for the treatment of rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies.
  • Indicated for the treatment of granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis) and microscopic polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids.
  • Indicated for the treatment of moderate to severe pemphigus vulgaris (PV) in adult patients.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Rituximab (Rituxan) is indicated for the treatment of various conditions including follicular lymphoma, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, rheumatoid arthritis, diffuse large B-cell lymphoma (DLBCL), granulomatosis with polyangiitis, and pemphigus vulgaris.
  • A total of 42 systematic reviews/meta-analyses were reviewed to gather information about rituximab's safety and effectiveness in comparison to other drugs.
  • In patients with advanced follicular lymphoma, rituximab showed significant progression-free survival benefits as maintenance therapy after first-line or relapse treatments. However, it was associated with somewhat higher toxicity compared to observation alone.
  • For ANCA-associated vasculitis remission achievement and maintenance, rituximab proved effective and safer than azathioprine respectively. It also demonstrated comparable efficacy to cyclophosphamide in achieving remission.
  • In treating rheumatoid arthritis patients, rituximab significantly decreased anti-citrullinated peptide antibodies titers - a benefit not seen with TNF inhibitors or abatacept, indicating its direct immunomodulatory effect that could be pivotal for certain patient profiles.
  • When combined with the CHOP chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), rituximab is beneficial for patients suffering from DLBCL, enhancing their outcomes considerably making it a standard management option for this condition.
  • In pediatric populations suffering from B-cell Non-Hodgkin’s Lymphoma, rituximab shows similar benefits as those observed in adult populations.
  • Rituximab's usage during pregnancy, particularly while managing diseases such as ANCA-associated vasculitis, suggests potential inclusion into management plans where benefits might outweigh risks but requires careful consideration and monitoring.

Product Monograph / Prescribing Information

Document TitleYearSource
Rituxan (rituximab) Prescribing Information.2021Genentech Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: a systematic review and network meta-analysis of randomized trials.2024American Cancer Society
Incidence, clinical features, management, and outcomes of ANCA-associated vasculitis in pregnancy- A systematic literature review.2023Sarcoidosis Vasculitis And Diffuse Lung Diseases
Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study.2023Clinical and Experimental Rheumatology
Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: a systematic review.2023Clinical Rheumatology
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis.2023Advances in Rheumatology
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1 - Treatment of granulomatosis with polyangiitis and microscopic polyangiitis.2023RMD Open
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV.2023RMD Open
The efficacy and safety of rituximab in ANCA-associated vasculitis: a systematic review.2022Biology
Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: a single-arm meta-analysis.2022Frontiers in Oncology
Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: a meta-analysis of prospective clinical trials.2022Frontiers in Immunology
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.2022Blood Cancer Journal
Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders.2022Frontiers in Immunology
Vasculitis induced by biological agents used in rheumatology practice: a systematic review.2022Archives of Rheumatology
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review.2021Autoimmunity Reviews
RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis.2021Translational Cancer Research
Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies.2021Rheumatology
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis.2021Scientific Reports
Granulomatosis with polyangiitis and microscopic polyangiitis: a systematic review and meta-analysis of benefits and harms of common treatments.2021ACR Open Rheumatology
R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis.2021Acta Oncologica
De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris – A systematic review.2021Expert Opinion on Biological Therapy
Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.2021Annals of Hematology
Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis. 2021Reumatologia Clinica
Obinutuzumab-related adverse events: a systematic review and meta-analysis.2021Hematological Oncology
Network meta-analysis-based comparison of first-line steroid–sparing adjuvants in treatment of pemphigus vulgaris and pemphigus foliaceus.2021Journal of American Academy of Dermatology
Most appropriate conventional disease-modifying antirheumatic drug to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis.2021Arthritis Care & Research
A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis.2020Medicine
Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.2020Clinical Kidney Journal
Rituximab treatment for IgA vasculitis: a systematic review.2020Autoimmunity Reviews
Biological therapy in rheumatoid vasculitis: a systematic review.2020Clinical Rheumatology
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.2020Orphanet Journal of rare diseases
Burkitt and Burkitt-like lymphomas: a systematic review.2020Current Oncology Reports
Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices.2020Expert Review of Hematology
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.2020Annals of Rheumatic Diseases
What works when treating granulomatous disease in genetically undefined CVID? A systematic review.2020Frontiers in Immunology
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review.2020Leukemia
Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders.2019Frontiers in Immunology
Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis.2019Hematological Oncology
Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis.2019International Journal of Rheumatic Diseases
The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis.2019Platelets
Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and non-Hodgkin’s lymphoma: a systematic review and meta-analysis.2019BioDrugs
Efficacy of ibrutinib-based regimen in chronic lymphocytic leukemia: a systematic review.2019Journal of Hematology
The role of maintenance therapy in patients with diffuse large B cell lymphoma: a systematic review and meta-analysis.2019Hematological Oncology

Clinical Practice Guidelines